Loading stock data…
HIMS
$28.98+1.81 (+6.66%)
Market ClosedLast close Jun 9
Hims & Hers Health, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Hims & Hers Health, Inc. in the Healthcare sector is trading at $28.98. Wall Street consensus targets $26.61 (14 analysts), implying a -8.2% move over the next 12 months. The stock is currently 59% below its 52-week high of $70.43, remaining 14.3% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 79 is overbought against a weak tape. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply -8.2% downside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Overbought RSI 79 against a weak tape — risk of pullback
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$28.98
Potential Downside
0%
Whystock Fair Value$28.98
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus14 analysts
Hold
Mean target$26.61-8.2%
Range$21.00 – $35.00
Fundamentals
Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, and int...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-2.97%
Volume
Today's trading volume
25.05M
Recent News
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Is Hims & Hers Health, Inc. (HIMS) A Good Stock To Buy Now?
Is HIMS a good stock to buy? We came across a bearish thesis on Hims & Hers Health, Inc. on Valueinvestorsclub.com by Pridwen. In this article, we will summarize the bears’ thesis on HIMS. Hims & Hers Health, Inc.’s share was trading at $27.51 as of June 2nd. HIMS’s trailing and forward P/E were 57.14 and 58.82 […]
Hims CMO Appointment Highlights Longevity Focus And Raises Valuation Questions
Hims & Hers Health (NYSE:HIMS) has appointed Dr. Anant Vinjamoori as Chief Medical Officer of the Hims brand. The appointment highlights a push into longevity, preventive health, and peptide based care. Dr. Vinjamoori brings experience in clinical medicine, advanced diagnostics, and AI supported longevity programs from prior health technology roles. For investors tracking NYSE:HIMS, the appointment comes with the stock at a share price of $28.01, a three year return of 206.1%, and a five...
TD Cowen Raises GLP-1 Sales Forecast To $150B By 2030 – Industry Leaders LLY, NVO To Remain Dominant
TD Cowen expects around 59 million patients worldwide to be using GLP-1 therapies by the end of the decade, up sharply from its previous estimate of 46 million.
HIMS Stock Slides Overnight: CEO Sees Healthcare Potential In Anthropic's AI Leap As Lilly, WeightWatchers Turn Up The Heat
Competition is intensifying after WeightWatchers' Med+ program became available through LillyDirect.